Core Viewpoint - Travere Therapeutics, Inc. announced that the FDA has informed the company that an advisory committee is no longer needed for the supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS) [1] Group 1 - The sNDA for FILSPARI® remains under review by the FDA [1] - The Prescription Drug User Fee Act (PDUFA) target action date is set for January 13, 2026 [1]